HepaMerz

HepaMerz150 mg+100 mg

Tablet

L-Ornithine L-Aspartate + Pancreatin

City Overseas Ltd.

Product Code : 8173
MRP 180.00
8% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of HepaMerz 150 mg+100 mg

L-Ornithine-L-Aspartate / Pancreatin is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: Hepatic encephalopathy Digestion of food Inflammatory disease of the pancreas

Theropeutic Class

Digestive Enzyme

Pharmacology

Pancreatin is a preparation of Pancreatin having protease, lipase and amylase enzyme activity. Pancreatin hydrolyses fats to glycerol and fatty acids, changes protein into proteoses and derived substances and converts starch into dextrins and sugars. Pancreatin is employed in the conditions where the secretion of pancreatic juice is defcient.Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-L-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study aimed to assess the effectiveness and safety of LOLA in the management of hepatic encephalopathy.

Dosage & Administration of HepaMerz 150 mg+100 mg

1-2 tablets daily

Dosage of HepaMerz 150 mg+100 mg

1-2 tablets daily

Interaction of HepaMerz 150 mg+100 mg

If you use other drugs or over the counter products at the same time, the effects of L-Ornithine-L-Aspartate / Pancreatin may change. This may increase your risk for side-effects or cause your drug not to work properly. Tell your doctor about all the drugs, vitamins, and herbal supplements you are using, so that you doctor can help you prevent or manage drug interactions. L-Ornithine-L-Aspartate / Pancreatin may interact with the following drugs and products: Herbal products Over-the-counter medicines Prandase Precose Vitamins

Contraindications

Hypersensitivity to L-Ornithine-L-Aspartate / Pancreatin is a contraindication. In addition, L-Ornithine-L-Aspartate / Pancreatin should not be used if you have the following conditions: Gastrectomy Hypersensitivity Pancreatectomy Pregnant

Side Effects of HepaMerz 150 mg+100 mg

The following is a list of possible side-effects that may occur in medicines that contain L-Ornithine-L-Aspartate / Pancreatin. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away. Nausea Vomiting Abdominal Stomach pain Bloating Diarrhea

Pregnancy & Lactation

No data had found

Precautions & Warnings

Before using L-Ornithine-L-Aspartate / Pancreatin, inform your doctor about your current list of medications, over the counter products (e.g. vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.). Some health conditions may make you more susceptible to the side-effects of the drug. Take as directed by your doctor or follow the direction printed on the product insert. Dosage is based on your condition. Tell your doctor if your condition persists or worsens. Important counseling points are listed below. Avoid taking higher quantity than recommended dose Avoid use of this drug if allergic to it Consult your doctor before taking the drug in case of pregnancy or lactation Drink plenty of water when taking pancreatin Need doctor's consultation in abdominal cramps, blood in stools and loose motions Planning to get pregnant or breastfeeding

Drug Classes

Digestive Enzyme

Mode Of Action

Pancreatin is a preparation of Pancreatin having protease, lipase and amylase enzyme activity. Pancreatin hydrolyses fats to glycerol and fatty acids, changes protein into proteoses and derived substances and converts starch into dextrins and sugars. Pancreatin is employed in the conditions where the secretion of pancreatic juice is defcient.Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-L-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study aimed to assess the effectiveness and safety of LOLA in the management of hepatic encephalopathy.

Pregnancy

No data had found
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.